Background: Hepatitis E is caused by two viral genotype groups: human types and zoonotic types. Current understanding of the epidemiology of the zoonotic hepatitis E disease is founded largely on hospital-based studies.
Methods: The epidemiology of hepatitis E was investigated in a community-based surveillance study conducted over one year in a rural city in eastern China with a registered population of 400,162.
Results: The seroprevalence of hepatitis E in the cohort was 38%. The incidence of hepatitis E was 2.8/10,000 person-years. Totally 93.5% of the infections were attributed to genotype 4 and the rest, to genotype 1. Hepatitis E accounted for 28.4% (102/359) of the acute hepatitis cases and 68.9% (102/148) of the acute viral hepatitis cases in this area of China. The disease occurred sporadically with a higher prevalence during the cold season and in men, with the male-to-female ratio of 3∶1. Additionally, the incidence of hepatitis E increased with age. Hepatitis B virus carriers have an increased risk of contracting hepatitis E than the general population (OR = 2.5, 95%CI 1.5-4.2). Pre-existing immunity to hepatitis E lowered the risk (relative risk = 0.34, 95% CI 0.21-0.55) and reduced the severity of the disease.
Conclusions: Hepatitis E in the rural population of China is essentially that of a zoonosis due to the genotype 4 virus, the epidemiology of which is similar to that due to the other zoonotic genotype 3 virus.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909025 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087154 | PLOS |
Hepatol Int
January 2025
National Clinical Research Center for Digestive Disease, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background: Our previous research demonstrated that growth differentiation factor 15 (GDF15) exhibited superior predictive capability for metabolic dysfunction-associated steatohepatitis (MASH) development with an AUC of 0.86 at 10 years before disease diagnosis. However, the specific pathways and molecular mechanisms associated with GDF15 expression during MASH development remain to be fully investigated in humans.
View Article and Find Full Text PDFJ Viral Hepat
February 2025
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
The World Health Organisation (WHO) has set goals to eliminate hepatitis C (HCV) as a global health threat by 2030. To meet this goal, Australia must increase testing and diagnosis, including expanding access to care through community pharmacists. This study aims to explore community pharmacists' preparedness to discuss and offer HCV testing and treatment.
View Article and Find Full Text PDFJ Vector Borne Dis
January 2025
State Virology Laboratory, Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India.
Background Objectives: Co-infection of dengue virus and acute hepatitis A virus in paediatric population is a major health concern in endemic countries. This cross sectional retrospective study was conducted to evaluate the prevalence of hepatitis A virus among the clinically dengue suspected paediatric cases presented at our tertiary care centre during the two-year period (2022-2023).
Methods: A total of 747 dengue suspected paediatric clinical specimens were included in this study.
Comb Chem High Throughput Screen
January 2025
National Brain Research Centre, Manesar, Haryana, India 122052.
Introduction: The liver is essential for both the body's removal of waste materials and the metabolism of nutrients, it is critical for sustaining general health. However, a number of factors, including viral infections, immune system malfunctions, cancer, alcohol intake, and drug toxicity, are contributing to the rising prevalence of liver problems. Alternative approaches to liver disease treatment are being investigated due to the potential limitations of conventional medical treatments.
View Article and Find Full Text PDFFront Neurol
January 2025
Unidade Local de Saúde de São João, Porto, Portugal.
Background: Anti-CD20 monoclonal antibodies are a class of immunosuppressive drugs widely used in the treatment of central nervous system (CNS) inflammatory diseases, with well-established efficacy and safety. Although rare, these therapies can be associated with serious adverse events including hematological and infectious complications. This study aims to evaluate their safety and tolerability profile in real-world clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!